The GLP-1 market is growing fast. Here’s how much the most popular medications will cost you.

Medicare has delayed its BALANCE program for weight-loss drugs like Wegovy. Discover the new 'bridge program' that will offer ...

Medicare’s proposed pilot to cover GLP-1 drugs like Wegovy and Zepbound has been delayed. President Donald Trump once ...

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

Trump has touted his program for lower drug prices as “tremendous savings” for people on Medicare. Lowering the cost of ...

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

Novo Nordisk launched the high dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug.

Eli Lilly (LLY) stock slips as IQVIA data show that the company's obesity drugs Zepbound and Foundayo lag Novo’s (NVO) Wegovy ...

If you are among the 40% of people in the U.S. with obesity, one of the most powerful actions you can take for your health is working with your healthcare provider to treat it. Obesity is nothing to ...

Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo. Read ...

GLP-1 medications that suppress appetite are allowing people to better manage diabetes and obesity. As weight-loss drug ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.